There is a highly sophisticated way to treat some breast and ovarian cancers—a class of drugs called PARP inhibitors, designed to exploit the very defects that make tumors with certain mutations especially deadly. Yet this targeted approach to cancer therapy sometimes fails, and scientists have anxiously sought to understand why. Now, research at The Rockefeller […]
